UroMems awarded FDA IDE to use artificial urinary sphincter in pivotal trial
UroMems is set to enter the pivotal trial phase with its device for treating stress urinary incontinence (SUI). The company was …
UroMems is set to enter the pivotal trial phase with its device for treating stress urinary incontinence (SUI). The company was …
Novartis is stopping the development of ianalumab in hidradenitis suppurativa (HS) after a Phase IIb proof-of-concept trial failed to meet …
The UK Medical and Healthcare products Regulatory Agency (MHRA) has granted approval for Cybin to initiate the randomised EMBRACE study …
According to the US Centers for Disease Control and Prevention (CDC), a third of US teenagers are prediabetic, meaning that …
World Brain Day, celebrated annually on 22 July, serves as a call to action for increased neurological health awareness and …
World Brain Day, celebrated annually on 22 July, serves as a call to action for increased neurological health awareness and …
While more companies are using real-world data (RWD) and real-world evidence (RWE) in research, there are still barriers that continue …
Aptar Pharma has announced the acquisition of Mod3 Pharma's clinical trial materials manufacturing capabilities from SWK Holdings. Mod3 Pharma was previously …
AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain (AL) amyloidosis in two Phase III trials. A …
OKYO Pharma has reported encouraging top-line outcomes from the randomised Phase II trial of urcosimod (previously referred to as OK-101), …
This month, the Journal of the American Medical Association (JAMA) published a collaborative article between the Children’s Hospital of Philadelphia …
The UK Government will enhance manufacturing and commercialisation as it looks to harness the value of the life sciences sector …
The White House’s decision to safeguard $400m in President's Emergency Plan for AIDS Relief (PEPFAR) funding to support the global …
SELLAS Life Sciences’ CDK9 inhibitor, SLS009, for relapsed/refractory acute myeloid leukaemia (r/r AML) is set to advance after it met …
Hengrui Pharma and Kailera Therapeutics have reported positive topline data from the former’s Phase III trial (HRS9531-301) of subcutaneous injections …